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Diffuse alveolar hemorrhage (DAH) is a clinical condition characterized by the rapid
onset of dyspnea, hemoptysis and acute respiratory failure (ARF). It is commonly
caused by autoimmune systemic vasculitis, pulmonary infections, drugs and tumors.
Here, we report a case of DAH caused by frequent cannabis smoking. A 16-year old
boy presented with hemoptysis, dyspnea and ARF soon after laparoscopic surgery
for varicocele in general anesthesia. The suspected diagnosis of DAH emerged from
the initial chest radiography, and it was then confirmed by CT scan findings and the
bronchoalveolar lavage. His general conditions completely recovered after only 24 h
of oxygen supplementation and after intravenous corticosteroid and antibiotic therapy.
This is the first pediatric case of DAH related to smoking marijuana, even though
the inhalational anesthetic agent sevoflurane might have also been involved in this
pathogenesis. Other possible causes of DAH have been considered. Negative-pressure
pulmonary edema could be ruled out because no clinical evidence of upper airway
obstruction was observed during general anesthesia and throughout the surgery. In
addition, a possible causative role of cannabis additives/contaminants could not be
excluded. Given the high prevalence of cannabis smoking in young people and that DAH
can be a complication in cannabis smokers, a careful history and high index of suspicion
are recommended as part of the pre-operative assessment before these patients are
proceeded to receive general anesthesia.
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BACKGROUND
Diffuse alveolar hemorrhage (DAH) is a medical condition characterized by bleeding into the
alveolar spaces of the lungs due to the disruption of the alveolar-capillary basement membrane.
It manifests as rapid onset of dyspnea, hemoptysis and acute respiratory failure (ARF) (1).
The etiology can vary from autoimmune systemic vasculitis to pulmonary infections, drugs, and
tumors, which can lead to pulmonary capillaritis, bland pulmonary hemorrhage, or diffuse alveolar
damage (2–4). In particular, a strong association between DAH and the use of recreational drugs,
such as cocaine, amphetamine and crack, has been well-documented (5, 6).
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Regarding pot smoking and DAH, literature is very poor since
only few cases in adult patients have been described so far (7–11).
Nonetheless, the prevalence of this recreational drug is increasing
worldwide, including Italy where the lifetime prevalence of
cannabis use is 27% among adolescents aged 16 years old
(12, 13). In this regard, Italy has experienced a boom in light
cannabis smoking since Law No. 242 went into effect December
2016, legalizing hemp cultivation and commercialization but
paradoxically not its consumption (14).
In this scenario, it is more important than ever to raise
a greater awareness about cannabis smoking and all the
medical problems resulting from this habit. Here, we report
an unprecedented case of DAH caused by cannabis abuse in a
pediatric patient.
CASE PRESENTATION
A 16-year old boy underwent laparoscopic surgery for varicocele.
His past medical history was uneventful, except for febrile
seizures during early childhood. He had no allergies, history
of recurrent pneumonia or other chronic respiratory diseases.
Likewise, his family history was unremarkable. Smoking habits
were asked but not disclosed. Complete blood cells count,
liver and kidney function tests and first level coagulation
studies (platelets count, prothrombin time test, activated partial
thromboplastin time, and fibrinogen) were all normal before
the general anesthesia. According to the American Society of
Anesthesiologists (ASA) risk classification1, he was a healthy
patient (ASA 1).
Prior to the operation, the patient was given general
anesthesia consisting of propofol (2 mg/kg) and rocuronium
(0.6 mg/kg), with remifentanil (0.25 mcg/kg/min) for intubation.
General anesthesia was maintained with 2% sevoflurane and
remifentanil (0.25–0.125 mcg/kg/min). Sugammadex (2 mg/Kg)
was administered before extubation (TOF ratio > 0.9).
Both surgery and extubation were conducted without any
complications and the patient had no obvious signs of upper
airway obstruction, neither cough nor laryngospasm.
Thirty minutes after waking up, he manifested hemoptysis,
dyspnea, and ARF. He was alert, tachypnoeic, and
normothermic. His Glasgow Coma Scale was 15, and his
initial vital signs were: pulse 80 bpm, blood pressure 90/60
mmHg and oxygen saturation averaging 73% on room air.
Arterial blood gas analysis revealed: pH 7.37; pCO2 39.6
mmHg (5.27 kPa); pO2 39.5 mmHg (5.26 kPa); oxyhemoglobin
(oxyHb) 73.7%; and HCO3− 23.1 mEq/L. Otorhinolaryngoiatric
evaluation with nasal and laryngeal fibro-endoscopy unveiled
no evidence of previous bleeding from the upper respiratory
tract. Respiratory auscultation revealed diffuse rhonchi, with
no other remarkable signs. His initial chest x-ray (Figure 1)
showed infiltrative opacification pattern mainly seen in the mid
zones with apical sparing suggestive for impaired pulmonary
microcirculation, raising the suspect of DAH (15, 16). To further
Abbreviations: ARF, acute respiratory failure; DAH, diffuse alveolar hemorrhage.
1https://www.asahq.org/standards-and-guidelines/asa-physical-status-
classification-system
FIGURE 1 | Chest x-ray at clinical onset of symptoms, consistent with diffuse
alveolar hemorrhage (DAH). There can be observed infiltrative opacification
pattern mainly seen in the mid zones with apical sparing suggestive for
impaired pulmonary microcirculation. There can be noticed areas of
subdiaphragmatic air due to laparoscopy.
FIGURE 2 | Chest CT scan without contrast medium confirming the diagnosis
of DAH.
investigate our hypothesis, a chest CT scan (Figure 2) was
performed, which revealed multiple dense opacities with blurred,
confluent margins due to diffuse alveolar involvement in the
pulmonary lobes.
Given the evidence of hypoxemic respiratory failure and the
suspect of DAH, the patient was transferred to the Intensive
Care Unit, where he was subjected to immediate bronchoalveolar
lavage, revealing the presence of abundant blood, but after the
bronchoalveolar lavage with 0.9% sodium chloride solution,
the bronchial mucosa appeared without signs of pathological
lesions. More specifically, three lavage of 50 mLs each were
done and afterwards 35, 35, and 50 mLs of BAL fluid were
retrieved. Direct microscopic examination showed leucocytes,
macrophages and bronchial epithelial cells. Further confirmation
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arrived from cytologic analysis of his bronchoalveolar lavage
secretions which described the presence of blood, 85% of
alveolar macrophages and 15% of granulocytes. Hemosiderin
was not assessed because hemoptysis started 4 h before and the
endoscopic appearance of the bleeding itself appeared to be very
recent, undergoing from <48 h. The patient was given fraction
inspired oxygen (FiO2) (40%; 12 L/min) by means of a Venturi
mask for ARF, intravenous ceftriaxone 2 g per day as antibiotic
prophylaxis and intravenous methylprednisolone 1 g per day for
anti-inflammatory action for 5 days, while waiting for the results
of microbial studies and autoimmune diseases screening (17).
Initial blood tests performed at Day 1 revealed: hemoglobin
levels 13.5 g/dl (135 g/L); leukocytosis 14.540 mm−3 (14.54
109/L), of which 83.7% were neutrophils, and normal platelet
count (221× 109 /L). Renal function, liver function, electrolytes,
coagulation studies (prothrombin time, activated partial
thromboplastin time, and fibrinogen) were all normal. Von
Willebrand factor deficiency was also ruled out on the basis of
Von Willebrand factor antigen and Ristocetin cofactor activities
which resulted within normal range (Von Willebrand factor
antigen was 90%, with a normal reference range between 57 and
147%; Ristocetin cofactor was 120% with a normal reference
range of 51–147% considering our patient’s specific age group).
Urinalysis was unremarkable, and direct microscopic exam
did not reveal any dysmorphic red blood cells (RBCs). The
diagnostic work-up, which included serological exams and blood
and sputum cultures for Streptococcus pneumoniae,Haemophilus
influenzae, Legionella pneumophila, Aspergillus, Mycobacterium
tuberculosis,Nocardia spp., Chlamydia pneumoniae,Mycoplasma
pneumoniae, Pneumocystis Jirovecii, Herpesviruses, and the
complete respiratory viral panel, ruled out any pulmonary
infections. An extensive rheumatological serologic evaluation
including CRP, c-ANCA, p-ANCA, ANA, and ENA panel
came back negative as well. Lastly, the echocardiography was
completely normal, excluding any congenital or acquired
cardiomyopathy as well as pulmonary hypertension.
Questioned on smoking habits, the boy revealed to be a
frequent cannabis smoker since few years. He admitted to have
smoked about 1–2 joints per day in the last month before surgery
and to have used a marijuana smoking device known as “water
bong” at least once. Moreover, he denied having used any other
type of street drugs.We therefore performed a toxicological urine
test that resulted positive for cannabinoids. Cocaine was not
tested since the patient’s parents declined their consent.
The patient’s general conditions rapidly improved after 24
h: he was no longer dyspneic, and oxygen supplementation
was stopped on day 2 of hospitalization after a second
chest radiograph (Figure 3) revealed the resolution of DAH.
He was discharged after 6 days with tapering prednisone.
Although he was recommended an ambulatory follow-up, his
parents declined.
DISCUSSION
DAH is due to disruption of the alveolar-capillary basement
membrane. Common initial signs and symptoms include
FIGURE 3 | Chest x-ray after 48 h showing both lungs clear of significant
parenchymal opacities and no signs of pleural effusions.
abrupt onset with cough, hemoptysis, fever, and dyspnea.
Some patients, however, present with severe hypoxemic
respiratory failure requiring immediate ventilatory support with
mechanical ventilation.
Illicit drug abuse, especially cocaine, amphetamine, and
synthetic cannabinoids, has been associated with DAH (5–
8). To date, only five cases of DAH related to marijuana
have been published, all in adult subjects. Two of these
cases were individuals that had inhaled synthetic cannabinoid
(7, 8), one had smoked marijuana using a homemade
plastic bong (9) and died of DAH, one had smoked several
marijuana joints (10) and the last one was a frequent cannabis
smoker receiving general anesthesia (11). In addition, in
a 16–year–old boy a case of hemoptysis was reported in
association with cannabis smoking mixed with micro-particles
of silicon dioxide (18). To our knowledge, our patient is
the first pediatric case of DAH associated with non-synthetic
cannabis smoking.
Cannabis, also known as marijuana, pot or weed, is the most
popular recreational drug worldwide as it is easy to find and
can be bought at an affordable price (19). According to the 2015
European School Survey Project on Alcohol and Other Drugs
(ESPAD), cannabis is rated as the most widespread illicit drug
in ESPAD countries, with 16% of European students having
used cannabis at least once in their lifetime, ranging from 4%
in Moldova to 37% in the Czech Republic. Typically, lifetime
cannabis use is higher among boys than girls (19 vs. 14%,
respectively) (13).
Europe is not the only geographical area with high cannabis
use prevalence. A 2017 survey by the United States (US) Centers
for Disease Control and Prevention (CDC) through the Youth
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Risk Behavior Surveillance System (YRBSS) indicates that 35.6%
of US high schools students have used marijuana once or more
during their life, with 6.8% of them having tried it for the first
time before the age of 13 (8.3% male students; 5.3% female
students) (20). Interestingly, 19.8% of US students reported
current marijuana use at least once during the 30 days before
taking the survey.
Even though cannabis consumption can result in generalized
airway inflammation with evidence of respiratory epithelial
cell injury and damage to alveolar macrophages (21), its
potential role in DAH has not been well-investigated. Here,
we show that DAH is associated with frequent cannabis
smoking, further supporting a detrimental effect of weed
smoking habit on the respiratory system of otherwise
healthy individuals.
Other etiologies could explain DAH occurring after general
anesthesia, such as negative-pressure pulmonary edema (NPPE).
This is a well-recognized post-operative clinical entity which
has been described as causative factor of DAH. Generation of a
negative pleural pressure on inspiration against an upper airway
obstruction is the mechanism of stress failure of the alveolar-
capillarymembrane inNPPE (22). In our case, we did not observe
airway obstruction during general anesthesia and the surgery was
conducted without any complications.
Another limitation of our study is that we cannot rule out
that the anesthetic drugs used for induction and maintenance
of general anesthesia could have also played a role in
DAH. All of them are somehow related to pulmonary
complications. For instance, sugammadex is known to cause
negative-pressure pulmonary edema, remifentanil is related
to respiratory depression, as well as propofol to acute lung
injury and pulmonary edema2 Regarding rocuronium, no
evidence of lung injury effect exists. In some cases sevoflurane
has been associated to DAH. In the literature, 4 cases of
sevoflurane-related DAH have been reported, with one of them
being a cannabis smoker (11, 23–25). In this regard, it has
been proposed that sevoflurane, as well as other inhalational
anesthetic agents, could increase alveolar permeability, oxidative
stress and inflammatory response, thereby promoting DAH.
Moreover, in one case report, a young adult patient developed
DAH due to negative-pressure pulmonary edema as a result
of muscle rigidity after a bolus of remifentanil. This was
reversed by neuromuscular blockade with sugammadex (26).
Thus, it is not only difficult to disentangle the possible
additive or synergistic effects of anesthetic drugs and cannabis
smoke, but it is also tempting to speculate that the chronic
cannabis use may have predisposed our patient to airway
inflammation and alveolar epithelial damage, which could
have been exacerbated by sevoflurane inhalation, resulting in
inhalational injury.
Our speculation is limited by a paucity of information about
our patient’s smoking habits. We did not know how long our
2https://www.pneumotox.com/drug/index/
patient had been smoking and the declared amount of joints
per day may be underestimated. Moreover, we did not know
how much cannabis and tobacco were used to prepare joints.
For instance, psychoactive inert herbs or synthetical additives
may be mixed to Cannabis. Even if a causative role of cannabis
additives/ contaminants in airways inflammation could not
be excluded, our patient declared to smoke only Cannabis
sativa and anatomopathological analysis of his bronchoalveolar
lavage secretions did not describe the presence of any additives
or contaminants.
In addition to that, cocaine use should be considered
in the differential diagnosis of DAH. However, we did not
know if our patient ever used cocaine since he denied
this habit and his parents declined their consent to the
specific test.
Another limitation is the incomplete and perhaps unreliable
patient history, combined with lack of any information regarding
the follow-up due to the refusal of the patient’s parents to
collaborate. The follow-up would possibly have corroborate our
speculation, because it is unlikely that smoking joints had been
stopped and, if there actually was a close link to the DAH, it might
have relapsed.
CONCLUSIONS
Although it is still not clear how high the risk of cannabis-
related DAH may be, the high prevalence of cannabis smoking
among young adolescents calls for a more thorough assessment
of this potential risk before any surgery under general
anesthesia. In this regard, further studies are urgently needed
to confirm the association between marijuana smoking and
lung injury.
Therefore, despite the absence of a precise estimation of the
risk, we recommend caution in cannabis smokers undergoing
general anesthesia, as they may be more susceptible to develop
respiratory complications, such as DAH.
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